Elsherbiny Hadeel, Alnasser Sulaiman Mohammed, Aref Mohamed, ElSheikh Esraa, El-Sayed Sherein F, El-Malkey Nanees F, Alqahtani Haifa A, Alghamdi Abdullah A A, Nassan Mohamed A, Abd-ELhafeez Hanan H, Salem Gamal A
Department of Medical Physiology, Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia, 44519, Egypt.
Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Qassim, 51452, Saudi Arabia.
J Physiol Biochem. 2025 May 24. doi: 10.1007/s13105-025-01092-9.
Diabetic nephropathy is recognized as the predominant cause of end-stage renal disease worldwide. In reaction to metabolic stress, the peptide hormone spexin-14, is synthesized in both central and peripheral tissues. Its level is reduced in type II diabetes mellites and may play a role in glucose metabolism. However, in the context of DN, the mechanisms through which spexin exerts its effects remain largely unknown. This research employed a rat model of DN to explore the therapeutic potential and the underlying mechanisms associated with spexin treatment. For the development of this experimental model, rats were subjected to an eight-week regimen of a high-fat, high-fructose diet prior to receiving a single dose of streptozotocin (35 mg/kg body weight). Subsequently, spexin was administered subcutaneously on a daily basis for a duration of eight weeks at a dosage of 50 µg/kg body weight. The evaluation methods employed encompassed renal function assessments, macromorphological examinations, histopathological evaluations, and analyses of inflammatory and oxidative stress mediators. Additionally, immunohistochemical staining for NF-kB and E-cadherin, along with PCR analysis of mTOR, Bcl2, and Bax gene expressions in renal tissues, were conducted. Following the administration of spexin to the diabetic rats, there was a significant reduction in serum levels of glucose, urea, creatinine, and inflammatory cytokines (IL-1β, TNF-α), alongside a marked restoration of antioxidant enzyme activities. Furthermore, a significant decline in the levels of NF-κB, mTOR, and Bax was noted and accompanied with increased expressions of Bcl-2 and E-cadherin proteins. The observed improvements in histopathological changes significantly corroborated the biochemical results. In summary, spexin has proven to be effective in alleviating DN by its capacity to mitigate metabolic disturbances, oxidative stress, inflammation, and apoptosis.
糖尿病肾病被公认为是全球终末期肾病的主要原因。作为对代谢应激的反应,肽激素spexin-14在中枢和外周组织中均有合成。其水平在2型糖尿病中降低,可能在葡萄糖代谢中发挥作用。然而,在糖尿病肾病的背景下,spexin发挥作用的机制在很大程度上仍不清楚。本研究采用糖尿病肾病大鼠模型来探索spexin治疗的潜在疗效及其相关潜在机制。为建立该实验模型,大鼠在接受单剂量链脲佐菌素(35mg/kg体重)之前,先接受为期八周的高脂肪、高果糖饮食方案。随后,以50μg/kg体重的剂量每天皮下注射spexin,持续八周。所采用的评估方法包括肾功能评估、大体形态学检查、组织病理学评估以及炎症和氧化应激介质分析。此外,还进行了肾组织中NF-kB和E-钙黏蛋白的免疫组化染色,以及mTOR、Bcl2和Bax基因表达的PCR分析。对糖尿病大鼠给予spexin后,血清葡萄糖、尿素、肌酐和炎症细胞因子(IL-1β、TNF-α)水平显著降低,同时抗氧化酶活性明显恢复。此外,还观察到NF-κB、mTOR和Bax水平显著下降,并伴随Bcl-2和E-钙黏蛋白表达增加。组织病理学变化的改善显著证实了生化结果。总之,spexin已被证明可通过减轻代谢紊乱、氧化应激、炎症和细胞凋亡来有效缓解糖尿病肾病。